Navigation Links
EntreMed Initiates Plans for China Office
Date:3/5/2012

actors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; our history of losses and expectation of incurring continued losses; the risk that our stockholders may not approve our recent financing transaction and our ability to repay the indebtedness incurred in connection with issuance and sale of the convertible notes if such notes are not converted into shares of common stock; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility of our common stock; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; declines in actual sales of Thalomid® resulting in reduced royalty payments; risks associated with our product candidates; any early-stage products under development; results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our  proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); and our ability to compete with larger, better financed biotechnology companies that may develop new approaches to the treatment of our targeted diseases or develop product candidates more advanced than ENMD-2076.  Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition.  We caution readers not to place undue reliance on any forward-looking statements, which only speak as
'/>"/>
SOURCE EntreMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
2. EntreMed Raises $20 Million to Support Clinical Development Program
3. EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
4. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
5. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
6. EntreMed to Present at The New York Society of Security Analysts Industry Conference
7. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
8. EntreMed Commences Continuous Dosing Clinical Trial For MKC-1
9. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
10. EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting
11. EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... DALLAS , Sept. 17, 2014   OTEMR, ... 2014 Edition Complete EHR certification, which designates that the ... the Stage 1 and Stage 2 Meaningful Use measures ... and Reinvestment Act (ARRA).  ONETOUCH EMR 2.0 was certified ... an Office of the National Coordinator-Authorized Certification Body (ONC-ACB) ...
(Date:9/17/2014)... -- Bayer HealthCare will present data on hemophilia A research ... Meeting, which takes place September 18-20 in ... shared through poster presentations, showcase Bayer,s commitment to advancing ... presented in a scientific forum. "With posters ... patients, Bayer is maintaining its commitment to research in ...
(Date:9/17/2014)... 2014  Lightbeam Health Solutions announced today an ... Direct ACO) to deploy the Lightbeam population health ... care while reducing costs. Photo - ... Accountable Care Organization is the ACO operating entity ... mission is to be the premier integrated health ...
Breaking Medicine Technology:OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 2Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 3Bayer to Present Data on Hemophilia Research at NHF in Washington, D.C. 4Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3
... AUSTIN, Texas, March 4, 2011 Vermillion, Inc. (Nasdaq: ... Gail Page, Vermillion,s Chief Executive Officer, will be presenting at ... Ritz Carlton, Laguna Niguel in Dana Point, CA. ... 1:00 p.m. Pacific. The presentation will be web cast and ...
... Halozyme Therapeutics, Inc. (Nasdaq: HALO ), ... extracellular matrix , today announced it plans to ... March 11, 2011 before the open of the financial ... call with the investment community at 8:00 a.m. PT ...
Cached Medicine Technology:Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA 2Vermillion to Present at the Roth 23rd Annual OC Growth Stock Conference March 13-16, 2011, Laguna Niguel, CA 3Halozyme Therapeutics to Host Fourth Quarter and 2010 Financial Results Conference Call on March 11 2
(Date:9/17/2014)... 17, 2014 (HealthDay News) -- Present-day Europeans are ... ancient humans, according to a new study. ... indigenous hunter-gatherers and early European farmers. But, a ... they are also the descendants of Ancient North ... from this third ancestral group, researchers from Harvard ...
(Date:9/17/2014)... HealthDay Reporter WEDNESDAY, Sept. 17, 2014 ... explain why antibiotic-resistant bacteria can thrive in a hospital setting. ... be the culprit. They can easily enter bacteria and move ... that makes bacteria drug-resistant, a new study finds. "The ... a class of antibiotic called carbapenems," said the study,s co-author, ...
(Date:9/17/2014)... Mathematics might be able to reduce the need for ... the autoimmune disease lupus. , In a new study, ... progression from nephritis kidney inflammation to interstitial ... reverse. A kidney biopsy is the only existing way ... its extent. , The model could also be used ...
(Date:9/17/2014)... Today, Blue Shield of California Foundation ... This body of grants aims to support California’s safety ... delivery, as well as to develop new coverage and ... strengthen the capacity of both domestic violence and healthcare ... entry points for domestic violence screening and services. , ...
(Date:9/17/2014)... In a country where 77% of inhabitants suffer ... how can Americans find healthy and fulfilling ways to ... , a 5-day interactive journey to putting stress into ... September 29th – October 3rd, the Hyland’s Stress Challenge ... topics that promote natural solutions for managing stress. , ...
Breaking Medicine News(10 mins):Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 2Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 3Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2Health News:Blue Shield of California Foundation Awards $5 Million in Third-Quarter Grants 2Health News:Stress Less with the Hyland's 5-Day Stress Challenge 2
... has increased its health budget by over 30 percent ... a new medical college//. ,"In a bid to ... medical education department budget to about Rs.1.52 billion. This ... billion," an official said. ,"The government not ...
... the June Journal of the American Society of Nephrology ... for chronic renal failure//. ,"Our results confirm an ... as an important causative factor in kidney disease," comments ... of the new study. ,Dr. Ejerblad and colleagues ...
... According to a new study by New York University School ... New York City are severely infected// with hepatitis B virus. ... the liver gets inflamed and can ultimately lead to cirrhosis ... 12 issue of Morbidity and Mortality Weekly, published by the ...
... new study, oral and intravenous antiviral drug may be ... ,Shingles, which is caused by varicella-zoster virus, is a ... at the University of Colorado and Health Sciences Center ... three women with moderate to severe pain following shingles. ...
... Middle school students have expressed a high degree of comfort ... schools are safer// , and make the students feel wanted. ... other schools. Psychologists from UCLA and UC ... than 70 sixth-grade classrooms in 11 Los Angeles public middle ...
... which is a severe form of food poisoning, now has ... team of researchers working at the University of Bristol//. ... researchers have narrowed down on a particular antibiotic called fosfomycin, ... effective in the laboratory, this drug has never been considered ...
Cached Medicine News:Health News:Kidney Failure three times pronounced with obesity 2Health News:Asian American Community Prone To Hepatitis B infection 2Health News:Asian American Community Prone To Hepatitis B infection 3Health News:Comfort Level, Maximum in Ethnically Diverse Schools 2Health News:Comfort Level, Maximum in Ethnically Diverse Schools 3
... semi-dry electrophoretic transfer cell and PowerPac ... Efficient Transfers. Minimal Buffer Requirements. ... and Reliable Transfers. Single-Step Locking ... Capacity to Transfer Multiple Gels. ...
... Transfers depurinated DNA and RNA from agarose ... as 15 minutes ,Increases speed and efficiency ... be applied to gel ,Part of an ... and UV crosslinking in 2.5 hours, versus ...
PosiBlot 30-30 Sponges...
PosiBlot 30-30 Pads...
Medicine Products: